CureVac stock drops more than 50% on news trial COVID vaccine 47% effective
June 16, 2021 at 17:10 PM EDT
Shares of Curevac NV tanked more than 50% in the extended session Wednesday after the pharma company said its trial COVID-19 vaccine showed an efficacy of 47% against the illness.
